DEWAYNE TOWNSEND
Veterinary in Ann Arbor, MI
License number
Michigan 6901009147
Issued Date
Apr 26, 2004
Expiration Date
Dec 31, 2008
Category
Veterinary Medicine
Type
Veterinarian
Address
Address
Ann Arbor, MI 48103
Professional information
Compositions And Methods For Treating And Preventing Cardiomyopathy And Heart Disease
US Patent:
2008026, Oct 23, 2008
Filed:
Feb 27, 2006
Appl. No.:
11/885304
Inventors:
Joseph M. Metzger - Ann Arbor MI, US
Dewayne Townsend - Ann Arbor MI, US
Soichiro Yasuda - Ann Arbor MI, US
Daniel E. Michele - Ann Arbor MI, US
Dewayne Townsend - Ann Arbor MI, US
Soichiro Yasuda - Ann Arbor MI, US
Daniel E. Michele - Ann Arbor MI, US
International Classification:
A61K 31/77, C12N 5/06, A61P 9/00
US Classification:
424 7838, 435375
Abstract:
The present invention relates to compositions and methods for treating and preventing heart disease. In particular, the present invention provides compositions comprising poloxamers (e.g., poloxamer 188-P1 88) and methods of using the same for treating and preventing heart disease (e.g., in subjects with muscular dystrophy) and for treating cells and tissue damage caused by ischemia and cell death (e.g., for treating dystrophin-deficient cells (e.g., myocytes)).
Compositions And Methods For Treating And Preventing Cardiomyopathy And Heart Disease
US Patent:
8580245, Nov 12, 2013
Filed:
Oct 29, 2010
Appl. No.:
12/915352
Inventors:
Joseph M. Metzger - Ann Arbor MI, US
Dewayne Townsend - Ann Arbor MI, US
Soichiro Yasuda - Ann Arbor MI, US
Daniel E. Michele - Ann Arbor MI, US
Dewayne Townsend - Ann Arbor MI, US
Soichiro Yasuda - Ann Arbor MI, US
Daniel E. Michele - Ann Arbor MI, US
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
A61K 31/77
US Classification:
424 7838
Abstract:
The present invention relates to compositions and methods for treating and preventing heart disease. In particular, the present invention provides compositions comprising poloxamers (e. g. , poloxamer 188-P188) and methods of using the same for treating and preventing heart disease (e. g. , in subjects with muscular dystrophy) and for treating cells and tissue damage caused by ischemia and cell death (e. g. , for treating dystrophin-deficient cells (e. g. , myocytes)).